Technology Platform - Dual Specific Platform - Nanjing Leads Biolabs Co.,Ltd

TECHNOLOGY PLATFORM

Antibody Discovery Platforms Bi/Multi-Specific Antibody ADCC and CDC Enhanced Antibodies Cell Line Development In Vitro & In Vivo Screening and Evaluation Platforms CMC Scientific Publications

Bi/Multi-Specific Antibody

Bi/multi-Specific Antibody can recognize and bind to two or more different antigens or epitopes. Through our bi/multi-Specific platform, molecules with unique MOA or synergistic effects can be obtained through the combination of different targets.

CD3 Engager:

Our CD3 Engager has a variety of designs for different targets, including symmetric/asymmetric, anti-CD3 activity and anti-TAA target activity fine-tuning, different valency and spatial structure, to achieve a balance between efficacy and safety.

Bifunctional fusion protein/bispecific antibodies:

Simultaneously targeting two different targets may exert bifunctional effect or reduce the toxicity to achieve better clinical results.

Bi-paratope Antibody:

This type of antibody is directed against two different epitopes of the same target to obtain a molecule with higher avidity and unique MOA.

Wechat QR code

Headquarters and R&D Center：18 E. Jialingjiang Str., Bldg. 03 Fl. 7, Nanjing 210019, P.R.C.

Pilot and production：122 Huakang Rd., Bldg. 05, Jiangbei New Area, Nanjing 210031,P.R.C.

025-83378099 wlzb@leadsbiolabs.com